M. from clades B, D, and E. In addition, vaccinees’ sera displayed significant neutralizing activity against 5 of 14 main isolates tested, including one X4 disease and two dualtropic viruses (from clade B) and two R5 viruses (from clades B and Nimodipine C). This is the first demonstration of the induction by a candidate HIV vaccine constructed from clade B laboratory strains of HIV of neutralizing activity against R5 and clade C main isolates. The data suggest that, by virtue of their ability to induce cross-clade immune responses, appropriately formulated HIV vaccines based on a finite quantity of HIV isolates may ultimately be able to protect against the wide range of HIV isolates influencing the populations of many geographic regions. Progress in the development of an effective vaccine for human being immunodeficiency disease type I (HIV-1) has been gauged in large part by the ability to elicit measurable virus-specific CD8+ cytotoxic T lymphocytes (CTLs) and neutralizing antibodies (Abs) as essential correlates of protecting immune reactions (8, 29, 36). The major focuses on for neutralizing Abdominal muscles are gp120 and, to a lesser degree, the transmembrane gp41 envelope glycoproteins of the disease (8). The 1st HIV vaccines advanced to medical trials were based on recombinant envelope (Env) subunits derived from T-cell line-adapted (TCLA) strains of the disease. While these vaccines generated neutralizing Abdominal muscles with variable and sometimes potent activity against the homologous TCLA HIV-1 vaccine strain, CTL activity was generally poor against heterologous TCLA strains (5, 25, 27, 41, 62) and the sera from vaccinated volunteers failed to neutralize most main isolates (28, 41, 42). Since serum-neutralizing Abs are considered critical to safety against most viral Rabbit Polyclonal to STAT5B (phospho-Ser731) infections (58) and have been shown to protect against HIV and simian immunodeficiency disease (SIV) infection in several animal models (2, 6, 7, 11, 20, 38, 40, 60, 63, 68, 76), the ability to induce neutralizing Abs is definitely thought to be an important characteristic of candidate HIV vaccines. To be protective against the many circulating subtypes of HIV, a vaccine will need to induce broad neutralizing anti-HIV Abs against main isolates, not only TCLA clade B strains (1, 44, 56). The current challenge for HIV vaccine design is to develop optimized vaccines able to elicit both stronger cellular immune Nimodipine reactions and broader neutralizing reactions against genetically varied viral species. One of the current strategies developed to induce both types of immune responses is called the prime-boost strategy, using a live poxvirus vector expressing the gene of HIV-1 to perfect the immune system and a recombinant subunit HIV-1 envelope protein to boost the immune response (13, 25, 26, 55, 73). Such candidate vaccines have been shown to induce both Nimodipine cellular and humoral reactions in animals (66, 67, 76), and a clade B-based canarypox vaccine was shown to elicit cross-clade CTLs in HIV-uninfected adults (19). However, the repertoire of neutralizing Abs induced by these prime-boost protocols in most volunteers was directed against the homologous TCLA strains from which the vaccine was made, a limited quantity of heterologous TCLA HIV strains, and a limited quantity of X4-tropic main clade B viruses (4, 12, 16, 17, 67, 74, 77). These initial results suggested that this vaccine routine induced a quite restricted humoral immune response. To test this assumption, the Abs induced by such a prime-boost regimen were tested for his or her ability to cross-react with V3 peptides and recombinant gp160 proteins derived from viruses of different clades and to neutralize viruses of different tropism from several clades. MATERIALS AND METHODS Subjects and specimens tested. Twenty human being sera were from the Division of AIDS (DAIDS), National Institutes of Health, from participants in trials carried out by the AIDS Vaccine Evaluation Group and sponsored from the National Institute of Allergy and Infectious Diseases. Sera were from HIV-uninfected volunteers, 18 to 60 years of age, of both sexes, who have been enrolled in AIDS Vaccine Evaluation Group protocol 029. This protocol consisted of an accelerated prime-boost immunization routine using recombinant canarypox disease (vCP205 [Pasteur Mrieux/Connaught Laboratories] expressing gp120MN, the transmembrane anchoring region of gp41LAI, GagLAI, and a portion of PolLAI) and rgp120SF2 in MF59 adjuvant (Chiron Corp, Emeryville, Calif.). HIV-uninfected subjects.